|
시장보고서
상품코드
2104682
폐암 액체생검 시장 : 기회와 전략(-2035년)Lung Cancer Liquid Biopsy Global Market Opportunities And Strategies To 2035 |
||||||
The Business Research Company
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.
가격
※ 부가세 별도
한글목차
영문목차
세계의 폐암 액체생검 시장은 2020년에 3억 6,190만 달러 규모가 되어, 2025년까지 연평균 복합 성장률(CAGR) 25.00% 이상으로 성장했습니다.
폐암 액체생검이란, 주로 혈액등의 체액중에 존재하는 순환 종양 DNA(ctDNA), 순환종양세포(CTC), 기타 바이오마커라고 하는 종양 유래 물질을 분석하는 것으로, 폐암 감지 및 경과 관찰을 실시하는 저침습인 진단 방법을 가리킵니다. 이 시장에는 폐암 진단 및 관리를 위한 액체생검 기반 제품이나 서비스를 개발·제공하는 바이오테크놀러지 기업, 진단 검사 기관, 의료기관등의 사업체가 창출하는 매출이 포함됩니다.이러한 검사는 폐암이 의심되는 환자나, 치료중, 혹은 치료 후 경과 관찰중 환자에 대해서, 종양 내과의, 병리의, 의료 종사자에 의해서 이용되고 있습니다.
폐암 액체생검 시장은 액체생검을 이용한 폐암 검출 및 관리를 위한 제품 및 서비스를 제공하는 사업체(조직, 개인 사업자, 파트너십)의 매출액으로 구성됩니다. 여기에는 장비, 소모품, 키트, 시약은 물론 소프트웨어 및 관련 서비스가 포함됩니다. 이러한 솔루션은 검체 채취 및 처리, 분석법 개발 및 시험, 데이터 분석 및 해석, 임상 의사 결정 지원 등 다양한 단계를 지원하며, 차세대 염기서열 분석(NGS) 및 중합효소 연쇄반응(PCR)과 같은 기술을 기반으로 합니다.
높은 흡연율 및 담배 소비량
과거에는 높은 흡연율과 담배 소비량이 폐암 액체생검 시장의 성장을 뒷받침해 왔습니다. 담배의 광범위한 사용으로 인해 폐암 발병률이 증가하면서, 효율적이고 조기 진단이 가능한 솔루션에 대한 강력한 수요가 발생했습니다. 의료 전문가들은 특히 장기 흡연자 등 고위험군에서 암을 검출하고 모니터링하기 위한 비침습적 기법으로 체액 생검 기술에 대한 관심을 점점 더 높여 왔습니다. 또한, 흡연과 관련된 건강 위험에 대한 인식이 높아짐에 따라 더 많은 사람들이 선별 검사를 받게 되었습니다. 예를 들어, 2025년 11월 기준, 프랑스에 본부를 둔 정부 간 국제 기구인 OECD(경제협력개발기구)에 따르면, 2023년에는 15세 이상 인구의 14.8%가 매일 흡연했습니다. 매일 흡연자 비율이 가장 높았던 나라는 튀르키예, 헝가리, 그리스 외에도 가입 후보국 및 파트너국인 인도네시아, 불가리아, 중국이었으며, 이들 국가에서는 4명 중 적어도 1명이 매일 흡연하고 있었습니다. 2023년 평균으로 보면, 남성의 18.5%가 매일 흡연했던 반면, 여성은 11.4%였습니다. 따라서 높은 흡연율과 많은 담배 소비량이 폐암 액체생검 시장의 성장을 견인했습니다.
실시간암 치료 최적화를 위한 ctDNA를 활용한 적응형 면역요법의 발전
폐암 액체생검 시장에서 사업을 전개하는 주요 기업들은 순환 종양 DNA(ctDNA)를 활용한 정밀 종양학 솔루션을 추진하고 있으며, 이를 통해 실시간 치료 모니터링, 적응형 면역요법 전략 및 환자 계층화의 개선이 가능해져 임상 결과 향상과 맞춤형 암 치료의 실현을 도모하고 있습니다. 예를 들어, 2025년 12월, 미국에 본사를 둔 생명공학 기업인 Cancer Research Institute는 진행성 폐암에 대한 정밀 면역요법을 선도하기 위해, 미국에 본사를 둔 헬스케어 기업인 Labcorp Holdings Inc.의 액체생검 기술을 활용하여 BR.36 제2/3상 임상시험의 다음 단계를 시작했습니다. 이 연구에서는 순환 종양 DNA(ctDNA)를 이용해 치료에 대한 초기 반응을 모니터링하고, 이에 따라 치료법을 조정하고 있습니다. 질병 진행 위험이 높은 환자에게는 면역요법과 화학요법의 병용 치료가 시행될 가능성이 있으며, 이를 통해 맞춤형 의료 전략이 향상됩니다. 존스 홉킨스 키멜 암 센터를 비롯한 주요 연구 기관이 주도하는 이 임상시험은 치료 성과 향상을 목표로 하며, 실시간암 관리에 있어 ctDNA를 중요한 도구로 확립하고자 합니다.
세계 폐암 액체생검 시장은 비교적 집중되어 있으며, 대기업들이 시장에서 사업을 전개하고 있습니다. 2024년에는 시장 상위 10개 주요 기업이 전체 시장의 28.08%를 차지했습니다.
자주 묻는 질문
목차
제1장 주요 요약
제2장 목차
제3장 표 리스트
제4장 그래프 리스트
제5장 보고서 구성
제6장 시장 특징
제7장 폐암 액체생검 시장 : 주요 제품 및 서비스 개요
제8장 세계의 폐암 액체생검 시장 : 매력 스코어 및 분석
제9장 폐암 액체생검 시장 : 공급망 분석
제10장 주요 시장 동향
제11장 세계의 폐암 액체생검 : 성장 분석 및 전략적 분석 프레임워크
제12장 세계의 폐암 액체생검 시장 : 규모 및 성장 분석
제13장 세계의 폐암 액체생검 : 총잠재 시장(TAM) 분석
제14장 세계의 폐암 액체생검 : 시장 세분화
제15장 폐암 액체생검 시장 : 지역별, 국가별 분석
제16장 아시아태평양 시장
제17장 동남아시아 시장
제18장 북미 시장
제19장 서유럽 시장
제20장 남미 시장
제21장 동유럽 시장
제22장 중동 시장
제23장 아프리카 시장
제24장 경쟁 구도와 기업 개요
제25장 기타 주요 기업 및 혁신 기업
제26장 경쟁 벤치마킹
제27장 경쟁 대시보드
제28장 폐암 액체생검 시장 : 기업 평가 매트릭스
제29장 폐암 액체생검 시장 : 주목 스타트업
제30장 주요 인수합병(M&A)
제31장 최근 동향 : 폐암 액체생검 시장
제32장 기회와 전략
제33장 폐암 액체생검 시장 : 결론과 제안
제34장 부록
JHS 26.08.11Lung cancer liquid biopsy refers to a minimally invasive diagnostic approach used to detect and monitor lung cancer by analyzing tumor-derived materials, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and other biomarkers, in bodily fluids, primarily blood. This market encompasses the revenues generated by entities, including biotechnology companies, diagnostic laboratories and healthcare institutions, that develop and provide liquid biopsy-based products and services for lung cancer diagnosis and management. These tests are used by oncologists, pathologists and healthcare providers for patients suspected of having lung cancer, as well as those undergoing treatment or post-treatment surveillance.
The lung cancer liquid biopsy market consists of sales by entities (organizations, sole traders and partnerships) that provide products and services for the detection and management of lung cancer using liquid biopsy. This includes instruments, consumables, kits and reagents, as well as software and related services. These solutions support various stages such as sample collection and processing, assay development and testing, data analysis and interpretation and clinical decision support and are based on technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR).
The global lung cancer liquid biopsy market was valued at $361.9 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 25.00%.
High Prevalence Of Smoking And Tobacco Consumption
During historic period, high prevalence of smoking and tobacco consumption supported the growth of the lung cancer liquid biopsy market. Widespread tobacco use increased the incidence of lung cancer, creating a strong demand for efficient and early diagnostic solutions. Healthcare providers increasingly turned to liquid biopsy technologies as a non-invasive method for detecting and monitoring cancer, particularly among high-risk populations such as long-term smokers. Additionally, rising awareness of smoking-related health risks encouraged more individuals to undergo screening. For instance, in November 2025, according to the OECD (Organization for Economic Co-operation and Development), a France-based intergovernmental international organization, 14.8% of people aged 15 and over smoked daily in 2023. The proportion of daily smokers was highest in Turkiye, Hungary and Greece, as well as in accession/partner countries Indonesia, Bulgaria and China, where at least one in four people smoked daily. On average, 18.5% of men smoked daily in 2023 compared to 11.4% of women. Therefore, high prevalence of smoking and tobacco consumption drove the growth of the lung cancer liquid biopsy market.
Advancing ctDNA-Guided Adaptive Immunotherapy For Real-Time Cancer Treatment Optimization
Key players operating in the lung cancer liquid biopsy market are advancing circulating tumor DNA (ctDNA)-driven precision oncology solutions, enabling real-time treatment monitoring, adaptive immunotherapy strategies and improved patient stratification to enhance clinical outcomes and personalized cancer care. For instance, in December 2025, Cancer Research Institute, a US-based biotechnology company, has initiated the next phase of its BR.36 Phase 2/3 clinical trial, leveraging liquid biopsy technology from Labcorp Holdings Inc., a US-based healthcare company, to guide precision immunotherapy for advanced lung cancer. The study uses circulating tumor DNA (ctDNA) to monitor early responses to treatment and adapt therapy accordingly. Patients showing high risk of disease progression may receive a combination of immunotherapy and chemotherapy, improving personalized care strategies. Led by leading research institutions including Johns Hopkins Kimmel Cancer Center, the trial aims to enhance treatment outcomes and establish ctDNA as a key tool in real-time cancer management.
The global lung cancer liquid biopsy market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 28.08% of the total market in 2024.
Lung Cancer Liquid Biopsy Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global lung cancer liquid biopsy market.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is evolving with growth in the number of listed companies, greater focus on ESG and sustainability positioning, increased focus on broadening shareholder base and rising frequency of M&A and corporate restructuring.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for lung cancer liquid biopsy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider lung cancer liquid biopsy market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework - Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth: - Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis: - Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation: - Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by product, by technology, by biomarker, by clinical application and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size And Growth: - Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies: - Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard: - Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments: - Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies: Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations: This section includes recommendations for lung cancer liquid biopsy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix: - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- 1) By Product: Instruments; Consumables, Kits And Reagents; Software And Services
- 2) By Technology: Multi-Gene-Parallel Analysis (NGS); Single-Gene Analysis (PCR Microarrays)
- 3) By Biomarker: Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
- 4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
- 5) By End User: Diagnostics And Imaging Centers; Hospitals; Academics And Research Centers; Other End Users
- Companies Mentioned: F. Hoffmann-La Roche Ltd; QIAGEN NV; Guardant Health Inc; Thermo Fisher Scientific Inc; Eurofins Scientific SE
- Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Canada; Mexico; Brazil; France; Germany; UK; Italy; Spain; Russia
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time-series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; lung cancer liquid biopsy indicators comparison.
- Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1 Executive Summary
- 1.1 Dashboard
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 Lung Cancer Liquid Biopsy Market Definition And Segmentations
- 6.4 Market Segmentation By Product (Instruments, Consumables, Kits And Reagents, Software And Services)
- 6.5 Market Segmentation By Technology (Multi-Gene-Parallel Analysis (NGS) And Single-Gene Analysis (PCR Microarrays))
- 6.6 Market Segmentation By Biomarker (Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells And Other Biomarkers)
- 6.7 Market Segmentation By Clinical Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring And Other Applications)
- 6.8 Market Segmentation By End User (Diagnostics And Imaging Centers, Hospitals, Academics And Research Centers And Other End Users)
7 Lung Cancer Liquid Biopsy Market, Overview Of Key Products/Services
8 Global Lung Cancer Liquid Biopsy Market Attractiveness Scoring And Analysis
- 8.1 Overview Of Market Attractiveness Framework
- 8.2 Quantitative Scoring Methodology
- 8.3 Market Attractiveness Scoring And Interpretation
- 8.4 Factor-Wise Evaluation
- 8.4.1 Growth Potential
- 8.4.2 Competitive Dynamics
- 8.4.3 Strategic Fit
- 8.4.4 Risk Profile
- 8.5 Strategic Implications And Recommendations
- 8.5.1 Strategic Implications
- 8.5.2 Strategic Recommendations
9 Lung Cancer Liquid Biopsy Market, Supply Chain Analysis
- 9.1 Overview of the Supply Chain and Ecosystem
- 9.1.1 Resources
- 9.1.2 Manufacturers
- 9.1.3 Distribution
- 9.1.4 End Users
10 Major Market Trends
- 10.1 Key Technologies & Future Trends
- 10.1.1 Biotechnology, Genomics And Precision Medicine
- 10.1.2 Artificial Intelligence And Autonomous Intelligence
- 10.1.3 Digitalization, Cloud, Big Data And Cybersecurity
- 10.1.4 Industry 4.0 And Intelligent Manufacturing
- 10.2 Major Trends
- 10.2.1 Advancing ctDNA-Guided Adaptive Immunotherapy For Real-Time Cancer Treatment Optimization
- 10.2.2 Rising Focus on AI-Integrated Multi-Omics for Minimal Residual Disease Detection and Recurrence Monitoring
- 10.2.3 Strategic Focus on AI-Driven Early Detection and Fragmentomics-Based Liquid Biopsy Innovations
11 Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework
- 11.1 Global Lung Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 11.1.1 Political
- 11.1.2 Economic
- 11.1.3 Social
- 11.1.4 Technological
- 11.1.5 Environmental
- 11.1.6 Legal
- 11.2 End User (B2B) Analysis
- 11.2.1 Diagnostics And Imaging Centers
- 11.2.2 Hospitals
- 11.2.3 Academics And Research Centers
- 11.2.4 Other End Users
12 Global Lung Cancer Liquid Biopsy Market Size And Growth Analysis
- 12.1 Historic Market Growth, 2020 - 2025, Value ($ Million)
- 12.1.1 Market Drivers 2020 - 2025
- 12.1.2 Market Restraints 2020 - 2025
- 12.2 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
- 12.3 Forecast Growth Contributors/Factors
- 12.3.1 Quantitative Growth Contributors
- 12.3.2 Drivers
- 12.3.3 Restraints
13 Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM) Analysis
- 13.1 Definition And Scope of Total Addressable Market (TAM)
- 13.2 Methodology And Assumptions
- 13.2.1 Total Addressable Market for the Lung Cancer Liquid Biopsy Market - Business to Business (B2B)
- 13.2.2 TAM Comparison Analysis
14 Global Lung Cancer Liquid Biopsy Market Segmentation
- 14.1 Global Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.2 Global Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.3 Global Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.4 Global Lung Cancer Liquid Biopsy Market, Segmentation By Clinical Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.5 Global Lung Cancer Liquid Biopsy Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.6 Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.7 Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, Kits And Reagents, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.8 Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Software And Services, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15 Lung Cancer Liquid Biopsy Market, Regional and Country Analysis
- 15.1 Global Lung Cancer Liquid Biopsy Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 15.2 Global Lung Cancer Liquid Biopsy Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
16 Asia-Pacific Market
- 16.1 Asia-Pacific Market Summary
- 16.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 16.3 Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.4 Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.5 Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.6 China Market
- 16.6.1 China Market Summary
- 16.6.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 16.6.3 China Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.6.4 China Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.6.5 China Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.7 India Market
- 16.7.1 India Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.7.2 India Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.7.3 India Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.8 Japan Market
- 16.8.1 Japan Market Summary
- 16.8.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 16.8.3 Japan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.8.4 Japan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.8.5 Japan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.9 Australia Market
- 16.9.1 Australia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.9.2 Australia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.9.3 Australia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.10 South Korea Market
- 16.10.1 South Korea Market Summary
- 16.10.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 16.10.3 South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.10.4 South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.10.5 South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.11 Taiwan Market
- 16.11.1 Taiwan Market Summary
- 16.11.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 16.11.3 Taiwan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.11.4 Taiwan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.11.5 Taiwan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
17 South East Asia Market
- 17.1 South East Asia Market Summary
- 17.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 17.2.1 South East Asia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.2.2 South East Asia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.2.3 South East Asia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.3 Indonesia Market
- 17.3.1 Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.3.2 Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.3.3 Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
18 North America Market
- 18.1 North America Market Summary
- 18.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 18.3 North America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.4 North America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.5 North America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.6 USA Market
- 18.6.1 USA Market Summary
- 18.6.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 18.6.3 USA Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.6.4 USA Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.6.5 USA Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.7 Canada Market
- 18.7.1 Canada Market Summary
- 18.7.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 18.7.3 Canada Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.7.4 Canada Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.7.5 Canada Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
19 Western Europe Market
- 19.1 Western Europe Market Summary
- 19.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 19.3 Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.4 Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.5 Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.6 UK Market
- 19.6.1 UK Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.6.2 UK Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.6.3 UK Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.7 Germany Market
- 19.7.1 Germany Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.7.2 Germany Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.7.3 Germany Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.8 France Market
- 19.8.1 France Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.8.2 France Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.8.3 France Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.9 Italy Market
- 19.9.1 Italy Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.9.2 Italy Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.9.3 Italy Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.10 Spain Market
- 19.10.1 Spain Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.10.2 Spain Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.10.3 Spain Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
20 South America Market
- 20.1 South America Market Summary
- 20.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 20.3 South America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.4 South America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.5 South America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.6 Brazil Market
- 20.6.1 Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.6.2 Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.6.3 Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
21 Eastern Europe Market
- 21.1 Eastern Europe Market Summary
- 21.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 21.3 Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.4 Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.5 Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.6 Russia Market
- 21.6.1 Russia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.6.2 Russia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.6.3 Russia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
22 Middle East Market
- 22.1 Middle East Market Summary
- 22.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 22.3 Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 22.4 Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 22.5 Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
23 Africa Market
- 23.1 Africa Market Summary
- 23.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 23.3 Africa Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 23.4 Africa Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 23.5 Africa Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
24 Competitive Landscape And Company Profiles
- 24.1 Lung Cancer Liquid Biopsy Market Competitive Landscape And Market Share 2024
- 24.1.1 Top 10 Companies (Ranked by revenue/share)
- 24.2 Company Profiles
- 24.3 F. Hoffmann-La Roche Ltd (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 24.4 Qiagen N.V. (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 24.5 Guardant Health Inc (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 24.6 Thermo Fisher Scientific Inc (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 24.7 Eurofins Scientific SE (Company Overview, Products and Services, Business Strategy, Financial Overview)
25 Other Major And Innovative Companies
- 25.1 NeoGenomics Laboratories Inc. (Company Overview | Products and Services)
- 25.2 Agilent Technologies Inc. (Company Overview | Products and Services)
- 25.3 Sysmex Corporation (Company Overview | Products and Services)
- 25.4 Illumina Inc. (Company Overview | Products and Services)
- 25.5 Biodesix Inc. (Company Overview | Products and Services)
- 25.6 SOPHiA GENETICS SA (Company Overview | Products and Services)
- 25.7 Caris Life Sciences Inc. (Company Overview | Products and Services)
- 25.8 Natera Inc. (Company Overview | Products and Services)
- 25.9 Bio-Rad Laboratories Inc. (Company Overview | Products and Services)
- 25.10 MDxHealth SA (Company Overview | Products and Services)
- 25.11 Foresight Diagnostics Inc. (Company Overview | Products and Services)
- 25.12 Myriad Genetics Inc. (Company Overview | Products and Services)
- 25.13 Menarini Silicon Biosystems Inc. (Company Overview | Products and Services)
- 25.14 Inivata Ltd. (Company Overview | Products and Services)
- 25.15 LungLife AI Inc. (Company Overview | Products and Services)
26 Competitive Benchmarking
27 Competitive Dashboard
28 Lung Cancer Liquid Biopsy Market - Company Scoring Matrix
- 28.1 Innovation & Brand Leaders
- 28.2 Brand-Driven Traditionalists
- 28.3 Niche or Regional Followers
- 28.4 Emerging Innovators
29 Upcoming Startups In the Lung Cancer Liquid Biopsy Market
30 Key Mergers And Acquisitions
- 30.1 Abbott Laboratories Acquired Exact Sciences Corporation
- 30.2 Veracyte Inc Acquired C2i Genomics Inc
- 30.3 Quest Diagnostics Acquired Haystack Oncology
31 Recent Developments In Lung Cancer Liquid Biopsy
- 31.1 Strengthening Precision Oncology Through Advanced Liquid Biopsy Integration In Clinical Research
- 31.2 Development Of Updated Platforms To Provide Advanced Cancer Profiling
32 Opportunities And Strategies
- 32.1 Global Lung Cancer Liquid Biopsy Market In 2030 - Countries Offering Most New Opportunities
- 32.2 Global Lung Cancer Liquid Biopsy Market In 2030 - Segments Offering Most New Opportunities
- 32.3 Global Lung Cancer Liquid Biopsy Market In 2030 - Growth Strategies
- 32.3.1 Market Trend Based Strategies
- 32.3.2 Competitor Strategies
33 Lung Cancer Liquid Biopsy Market, Conclusions And Recommendations
- 33.1 Conclusions
- 33.2 Recommendations
- 33.2.1 Product
- 33.2.2 Place
- 33.2.3 Price
- 33.2.4 Promotion
- 33.2.5 People
34 Appendix
- 34.1 Geographies Covered
- 34.2 Market Data Sources
- 34.3 Research Methodology
- 34.4 Currencies
- 34.5 The Business Research Company
- 34.6 Copyright and Disclaimer
